$68.50+1.40 (+2.09%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Exelixis (EXEL) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineSteady: revenue compounds ~12.8%/yr (FY21→FY25), net margin 33.7%, and free cash flow (~$875.8M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Returns vs FCF (108%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲7.0%
2,320.1
FY21→FY25CAGR +12.8%/yr
Net income ($M)▲50.1%
782.6
FY21→FY25CAGR +35.7%/yr
Free cash flow ($M)▲30.4%
875.8
FY21→FY25CAGR +26.1%/yr
Diluted EPS▲58.0%
2.78
buyback-liftedCAGR +40.2%/yr
What the receipts whisper · what a headline number hides
Share count
−12.6%
322.4mn → 281.9mn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$8.4M
−70.4% YoY in FY25 · 0.4% of revenue.
Returns vs FCF
108%
$947.5M returned vs $875.8M of FCF in FY25. The gap comes off the balance sheet (see net cash).
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
34¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 96.3% → 96.4%. Net margin 33.7% is more than double the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 2,435.9 | 2,320.1 | 2,168.7 | 1,830.2 | 1,611.1 | 1,435.0 | ▲7.0% | +12.8% |
Cost of revenue | 85.7 | 83.7 | 76.2 | 72.5 | 57.9 | 52.9 | ▲9.8% | +12.2% |
Gross profit | 2,350.3 | 2,236.4 | 2,092.5 | 1,757.7 | 1,553.2 | 1,382.1 | ▲6.9% | +12.8% |
Research & development | 824.3 | 825.0 | 910.4 | 1,044.1 | 891.8 | 693.7 | ▼9.4% | +4.4% |
Selling, general & admin | 533.9 | 518.7 | 492.1 | 542.7 | 459.9 | 401.7 | ▲5.4% | +6.6% |
Total operating expenses | 1,378.7 | 1,364.2 | 1,487.9 | 1,586.8 | 1,351.7 | 1,095.4 | ▼8.3% | +5.6% |
Operating incomefeeds ROC rank | 971.5 | 872.2 | 604.6 | 170.9 | 201.5 | 286.7 | ▲44.3% | +32.1% |
Other income, net | 64.0 | 69.0 | 77.0 | 86.6 | 32.9 | 7.5 | — | — |
Pretax income | 1,035.5 | 941.2 | 681.6 | 257.5 | 234.4 | 294.2 | ▲38.1% | +33.7% |
Income tax | 174.8 | 158.6 | 160.4 | 49.8 | 52.1 | 63.1 | ▼1.1% | +25.9% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 860.6 | 782.6 | 521.3 | 207.8 | 182.3 | 231.1 | ▲50.1% | +35.7% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 3.19 | 2.78 | 1.76 | 0.65 | 0.56 | 0.72 | ▲58.0% | +40.2% |
Diluted shares (mn) | 259.68 | 281.86 | 296.13 | 321.46 | 324.56 | 322.36 | ▼4.8% | −3.3% |
| Margins | ||||||||
Gross margin94th pct in Healthcare | 96.5% | 96.4% | 96.5% | 96.0% | 96.4% | 96.3% | ▼0.1pp | +0.1pp |
Operating margin | 39.9% | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% | ▲9.7pp | +17.6pp |
Net margin97th pct in Healthcare | 35.3% | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% | ▲9.7pp | +17.6pp |
† TTM = trailing four quarters through 2026-07-03.
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-10 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Exelixis' revenue last fiscal year?
Exelixis reported revenue of $2,320.1M in fiscal 2025, up 7.0% from fiscal 2024.
What was Exelixis' net income?
Exelixis reported net income of $782.6M in fiscal 2025, a net margin of 33.7%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

